Abound Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Abound Wealth Management's PTGX Position: Q3 2026 in Review
Abound Wealth Management held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 2 shares worth $282. The position accounts for ﹤0.01% of the portfolio, ranked #1109.
Abound Wealth Management first reported a position in PTGX in Q3 2024 and has held it in 9 quarters since. The position peaked at $350 in Q4 2025. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Abound Wealth Management held 2 shares of Protagonist Therapeutics worth $282 as of Q3 2026.
- Abound Wealth Management left its Protagonist Therapeutics share count unchanged in Q3 2026.
- Protagonist Therapeutics made up ﹤0.01% of Abound Wealth Management's portfolio in Q3 2026, its #1109 holding.
- Abound Wealth Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 9 quarters since.
- Abound Wealth Management's Protagonist Therapeutics position peaked at $350 in Q4 2025.
- 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Abound Wealth Management's 13F filing for Q3 2026, filed 26 Oct 2026.